TABLE 3.

Approved contraindications for fondaparinux in different countries or regions.

	Contraindications
China NMPA	①Patients known to have hypersensitivity to fondaparinux sodium or any excipient in the formulation;
	②Patients with clinically significant active bleeding;
	③Patients with acute bacterial endocarditis;
	④Patients with severe renal impairment, defined as a creatinine clearance <20 mL/min
Europe EMA	①Patients with severe renal impairment (creatinine clearance <30 mL/min);
	②Patients with body weight <50 kg;
	③Patients with active major bleeding, bacterial endocarditis;
	④patients with thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium;
	⑤patients with known hypersensitivity to fondaparinux sodium
US FDA	①Patients with severe renal impairment (creatinine clearance <30 mL/min);
	②Patients with active major bleeding;
	③Patients with bacterial endocarditis;
	④Patients with thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the ⑤presence of fondaparinux sodium;
	⑥Patients with body weight <50 kg (VTE prophylaxis only);
	⑦Patients with a history of severe hypersensitivity reactions to fondaparinux sodium (e.g., angioedema, anaphylactoid/anaphylactic reaction)